Class of Stock [Axis]
Series A Preferred Stock [Member]
Series B Preferred Stock [Member]
Series C Preferred Stock [Member]
Series X Preferred Stock [Member]
Equity Components [Axis]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Cash and Cash Equivalents [Axis]
US Treasury Securities [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Product and Service [Axis]
Federal Deposit Insurance Corp Limits [Member]
Concentration Risk Benchmark [Axis]
Revenue Benchmark [Member]
Concentration Risk Type [Axis]
Customer Concentration Risk [Member]
Customer [Axis]
Two Customers [Member]
Business Combination [Axis]
Scienture Inc [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Award Type [Axis]
SCN-102 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Merger Agreement [Member]
Debt Instrument [Axis]
Wellgistics Note [Member]
Danam Note [Member]
Related and Nonrelated Parties [Axis]
Wellgistics Health Inc [Member]
Tollo Health Inc. [Member]
Promissory Note [Member]
Legal Entity [Axis]
IPS, Softell and Bonum [Member]
Tollo [Member]
Related Party Transaction [Axis]
Integral Health [Member]
Losartan Potassium Oral Suspension [Member]
Pharmaceutical Product Resale [Member]
Wood Sage Note [Member]
Related Party [Member]
IPS, Softell And Bonum Health, Inc [Member]
Measurement Input Type [Axis]
Measurement Input, Share Price [Member]
Intangible Asset, Finite-Lived, Class [Axis]
SCN-107 [Member]
SCN 104 [Member]
SCN 106 [Member]
Streetville Note [Member]
Purchase Agreement [Member]
Secured Promissory Note A-1 [Member]
Secured Promissory Note B [Member]
Secured Promissory A-1 Note and B Note [Member]
Plan Name [Axis]
Option Plans [Member]
Restricted Stock [Member]
Vesting [Axis]
June 2029 [Member]
June 2030 [Member]
Title and Position [Axis]
Board of Directors Chairman [Member]
Second Amended and Restated 2019 Equity Incentive Plan [Member]
Warrant [Member]
Employee and Consultant [Member]
Share-Based Payment Arrangement, Option [Member]
Amended and Restated Agreement and Plan of Merger [Member]
Eat Well Investment Group Inc [Member]
Legacy Note [Member]
Ten Promissory Note [Member]
Exclusive License And Commercial Agreements [Member]
Long-Lived Asset, Class [Axis]
New Lease [Member]
IPS Lease [Member]
Location, Statement of Income, Balance [Axis]
Segments [Axis]
Single Reportable Segment [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement [Table]
Statement [Line Items]
ASSETS
Current assets:
Cash and cash equivalents
Accounts receivable, net
Inventory
Prepaid expenses
Deferred offering costs
Total current assets
Restricted cash
Property, plant and equipment, net
Notes receivable
Interest receivable
Intangible assets, net
Operating lease right-of-use assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued liabilities
Operating lease liability - current
Warrant liability
Note payable, net of debt discount - current portion
Development agreement liability - current portion
Total current liabilities
Note payable, net of debt discount
Development agreement liability
Deferred tax liability
Total liabilities
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock
Common stock, $0.00001 par value; 100,000,000 shares authorized; 41,064,146 and 40,630,815 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 1,448,331 and 1,015,000 shares unvested as of June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Common stock, shares unvested
Income Statement [Abstract]
Revenues
Cost of sales
Gross profit
Operating expenses:
Wage and salary expense
Professional fees
Accounting and legal expense
Technology expense
General and administrative
Research and development
Total operating expenses
Operating loss
Non-operating income (expense):
Change in fair value of warrant liability
Change in fair value of derivative liability
Loss on conversion of note payable
Loss on disposition of subsidiaries
Interest income
Interest expense
Total non-operating expense
Benefit (provision) for income taxes
Net loss
Net loss per common share
Basic
Diluted
Weighted average common shares outstanding
Basic
Diluted
Balances
Balance, shares
Common stock issued for services
Balance, shares
Common stock issued for cash pursuant to ELOC agreement, net of offering costs
Balance, shares
Equity line of commitment shares issued
Balance, shares
Conversion of note payable into common stock
Balance, shares
Stock-based compensation expense
Net loss
Restricted shares issued for services
Restricted shares issued for services, shares
Balances
Balance, shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
Amortization of intangible assets
Change in fair value of warrant liability
Change in fair value of derivative liability
Loss on conversion of note payable
Loss on disposition of subsidiaries
Stock-based compensation
Common stock issued for services
Amortization of debt discount
Amortization of right-of-use assets
Interest income
Changes in operating assets and liabilities:
Accounts receivable, net
Prepaid expenses and deposits
Inventory
Deferred offering costs
Lease liability
Accounts payable
Accrued liabilities
Development liability
Net cash used in operating activities
Cash flows from financing activities:
Proceeds from loan payable, related party
Proceeds from issuance of note payable, net of issuance costs
Gross proceeds from issuance of common stock
Net cash provided by financing activities
Net change in cash, cash equivalents and restricted cash
Total cash, cash equivalents and restricted cash at beginning of period
Total cash, cash equivalents and restricted cash at end of period
Reconciliation of cash, cash equivalents and restricted cash
Beginning of period:
Cash and cash equivalents
Restricted cash
End of period:
Cash and cash equivalents
Restricted cash
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for taxes
Supplemental disclosure of non-cash investing and financing activities:
Conversion of note payable into common stock
Equity line of commitment shares issued as offering costs
Issuance of note receivable in exchange for other receivables
Original issue discount and transaction expenses withheld from note payable principal
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Accounting Policies [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY
Acquisitions And Dispositions
ACQUISITIONS AND DISPOSITIONS
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS
Revenue from Contract with Customer [Abstract]
REVENUE RECOGNITION
Receivables [Abstract]
NOTES RECEIVABLE – RELATED PARTY
Inventory Disclosure [Abstract]
INVENTORY
Intangible Asset, Goodwill and Other [Abstract]
GOODWILL AND INTANGIBLE ASSETS
Debt Disclosure [Abstract]
DEBT
Equity [Abstract]
STOCKHOLDERS’ EQUITY
Warrants
WARRANTS
Share-Based Payment Arrangement [Abstract]
OPTIONS
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Leases
LEASES
Segment Reporting [Abstract]
SEGMENT REPORTING
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE
Restructuring Cost [Table]
Restructuring Cost and Reserve [Line Items]
SCHEDULE OF PURCHASE PRICE ALLOCATION
SCHEDULE OF DISAGGREGATED BY PRODUCT
SCHEDULE OF INVENTORY
SCHEDULE OF INTANGIBLE ASSETS WERE DETERMINED TO BE PRODUCT TECHNOLOGIES
SCHEDULE OF INTANGIBLE ASSETS
SCHEDULE OF FAIR VALUE OF WARRANT LIABILITY
SCHEDULE OF CHANGE IN WARRANT LIABILITY
SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS
SCHEDULE OF STOCK OPTION ACTIVITY
SCHEDULE OF DEVELOPMENT AGREEMENT LIABILITY
SCHEDULE OF BALANCE SHEET INFORMATION RELATED TO LEASES
SCHEDULE OF FUTURE MINIMUM PAYMENTS FOR OPERATING LEASE LIABILITIES
Segment Reporting [Table]
Segment Reporting [Line Items]
SCHEDULE OF SEGMENTAL FINANCIAL INFORMATION
Denominator for EPS – weighted average shares
Net loss
Nature of Operation, Product Information, Concentration of Risk [Table]
Product Information [Line Items]
Ownership rate
Treasury bills Instrument face value
Cash on deposit
Interest income
Concentration of credit risks and major customers percentage
Deferred offering costs to additional paid-in capital
Remaining deferred offering costs
Intangible assets
Goodwill
Asset impairment charges
Assets will be amortized over their expected remaining life
Outstanding warrants
Stock options
Exercisable shares of common stock
Provision for income taxes
Accumulated deficit
Cash in hand
Liabilities current
Working capital
ScheduleAcquisitionsAndDispositionsTable [Table]
Issuance of shares pursuant to Merger
Purchase price consideration
Common stock price per share
Discontinued operations
Common stock, at fair value
Series X Preferred Stock, at fair value
Total purchase consideration
Cash
Operating lease right-of-use assets
Intangible assets - product technologies
Accounts payable
Accrued liabilities
Loan payable, related party
Lease liability
Development agreement liability
Long-term convertible notes
Deferred tax liability
Net assets acquired
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Note principal amount
Prepaid debt
Notes payable
Other receivables
Maturity date
Interest rate
Note principal amount
Accounts payable
Operating lease liability
Note receivables
Gain (loss) on disposition of assets
Notes receivables
Interest income
Interest income
Disaggregation of Revenue [Table]
Disaggregation of Revenue [Line Items]
Total revenues
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Note receivables
Note maturity date
Finished goods
Inventory
Intangible Assets
Intangible Asset, Finite-Lived [Table]
Intangible Asset, Finite-Lived [Line Items]
SCN-102 – finite-lived (net of amortization of $908 for the six months ended June 30, 2026 and nil for the six months ended June 30, 2025)
Total intangible assets, net
Fair value of product technologies income approach description
Goodwill impaired method for fair value discerption
Share price
Shares
Impairment of intangible assets
Carrying amount of goodwill of reporting unit
Decrease in carrying amount of goodwill of reporting unit
Goodwill impairmrnt
Goodwill impaired method for fair value discerption
Estimated useful life
Goodwill
Undiscounted future cash flows
Undiscounted future cash flows carrying amount
Difference in undiscounted future cash flows and carrying amount
Impairment charges
Estimated future annual amortization expense
Principal amount
Original issue discount
Default interest rate
[custom:TransactionCosts-0]
Proceeds from Convertible Debt
Interest expenses
Lender's transaction costs, amortization
Interest rate
Cash
Placement agent fee
Deposits
Debt Instrument redemption description
Debt discount and issuance costs
Transaction costs
Unamortized discount
Notes payable, current
Notes payable, non-current
Accrued interest payable
Interest income
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Preferred stock ratio
Number of shares issued
Shares issued in merger
Common stock issued upon conversion
Number of restricted shares issued for services
Net proceeds
Restricted shares of common stock outstanding
Vested shares
Fair value of restricted common stock
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture
Stock-based compensation expense
Unrecognized stock compensation outstanding
Annual grant value of restricted common stock
Number of share available for issuance
WarrantsTable [Table]
Warrant issued
Warrants exercise price per share
Warrant term
Warrants exercised, shares
Dilutive price
Warrants exercised for shares
Number of warrants issued
Warrants outstanding
Change in fair value of warrant liability, gain (loss)
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Expected stock price
Exercise price
Remaining contractual term (years)
Expected volatility
Risk-free interest rate
Expected dividend yield
Outstanding as of December 31, 2025
Change in fair value
Rounding off
Outstanding as of June 30, 2026
Schedule Of Outstanding And Exercisable Warrants
Warrants outstanding, balance
Weighted average exercise price outstanding, balance
Contractual life in years, warrants outstanding
Intrinsic value warrants outstanding, balance
Warrants granted
Weighted average exercise price, warrants granted
Warrants forfeited, expired, cancelled
Weighted average exercise price, warrant forfeited, expired, cancelled
Warrants exercised
Weighted average exercise price, warrant exercised
Warrants outstanding, balance
Weighted average exercise price outstanding, balance
Intrinsic value warrants outstanding, balance
Warrants exercisable, balance
Weighted average exercise price exercisable, balance
Contractual life in years, warrants exercisabl
Intrinsic value warrants exercisable, balance
OptionsTable [Table]
Number of shares available for grant
Number of shares authorized
Compensation cost related to stock options granted
Number of stock options cancelled
Shares of common stock granted
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding, balance
Weighted-average exercise price outstanding, balance
Weighted-average contractual life in years, options outstanding
Intrinsic value option outstanding, balance
Number of options, granted
Weighted-average exercise price, granted
Number of options, cancelled
Weighted-average exercise price, cancelled
Number of options, Forfeited/expired
Weighted-average exercise price, Forfeited/expired
Number of options, exercised
Weighted-average exercise price, exercised
Number of options outstanding, balance
Weighted-average exercise price outstanding, balance
Intrinsic value option outstanding, balance
Number of options exercisable, balance
Weighted-average exercise price exercisable, balance
Weighted-average contractual life in years, options exercisable
Intrinsic value option exercisable, balance
Loss Contingencies [Table]
Stock issued, acquisition
Common stock conversion ratio
Stock issuance
Unpaid principal and accrued interest
Cash consideration
Total gross amount
Contract termination claims description
Repayments of related party debt
Principal portion of debt repaid
Accrued Interest
Principal portion of debt repaid
Accrued Interest
Outstanding balance of development agreement liability
Disputed value
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Current portion
Long-term portion
Total development agreement liability
Lessee, Lease, Description [Table]
Gain on disposition of lease
Acquired right of use liability
Operating lease expense
Schedule Of Balance Sheet Information Related To Leases
Weighted-average remaining lease term (in years)
Weighted-average discount rate
Schedule Of Future Minimum Payments For Operating Lease Liabilities
2026
Total minimum lease payments
Less: effect of discounting
Present value of future minimum lease payments
Less: current obligation under lease
Long-term lease obligations
Cost of sales
Gross profit
Research and development expense
Total operating expenses
Operating loss
Net loss
Total assets
Reportable segments not disclosed
Research and Development Expense
Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold
Professional Fees
Litigation Settlement, Fee Expense
[custom:TechnologyExpense]
Share-Based Payment Arrangement, Noncash Expense
Depreciation, Depletion and Amortization, Nonproduction
Warrant liability.
Development agreement liability current portion.
Development agreement liability.
Series X Preferred Stock [Member]
Common stock shares unvested.
Technology expense.
Change in fair value of warrant liability.
Gain loss on conversion of note payable.
Loss on disposition of subsidiaries.
Stock issued during period value equity line of commitment shares issued.
Stock issued during period shares equity line of commitment shares issued.
Interest income.
Warrants [Text Block]
Stock issued during period shares warrants exercised for cash.
Wellgistics Note [Member]
Danam Note [Member]
Stock issued during period shares warrants exercised for shares.
Conversion of note payable into common stock.
Equity line of commitment shares issued as offering costs.
Wellgistics Health Inc [Member]
Tollo Health Inc [Member]
Issuance of note receivable in exchange for other receivables.
Original issue discount and transaction expenses withheld from note payable principal.
Promissory Note [Member]
IPS, Softell and Bonum [Member]
Tollo [Member]
Integral Health [Member]
Fair value adjustment of warrants rounding off.
Share based compensation arrangement by share based payment award non option equity instruments exercisable.
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.
Share based compensation arrangement by share based payment award non option equity instruments grants in period weighted average exercise price.
Weighted Average Exercise Price, Warrants Forfeited.
Share based compensation arrangement by sharebasedpayment award non option equity instruments exercises in period weighted average exercise price
Share based compensation arrangement by share based payment award non option equity exercisable weighted average exercise price.
Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term.
Contractual Life Warrants, Warrants Exercisable Ending.
Share based compensation arrangement by share based payment award non options equity instrument outstanding intrinsic value.
Share based compensation arrangement by share based payment award non options equity instrument exercisable intrinsic value.
Wood Sage Note [Member]
Owned rate.
IPS Softell And Bonum Health Inc [Member]
Share based compensation arrangement by share based payment award options cancelled in period.
Employee and Consultant [Member]
Federal Deposit Insurance Corp Limits [Member]
Scienture Inc [Member]
Share based compensation arrangements by share based payment award options cancelled in period weighted average exercise price.
Fair value of product technologies income approach description.
Fair value shares.
Impairment of intangible assets.
Carrying amount of goodwill of reporting unit.
Decrease in carrying amount of goodwill of reporting unit.
Goodwill impairment charges.
Goodwill impaired method for fair value determinations.
Working capital.
Undiscounted future cash flows.
Undiscounted future cash flows carrying amount.
Difference in undiscounted future cash flows and carrying amount.
Acquisitions And Dispositions [Text Block]
Merger Agreement [Member]
Business combination recognized identifiable assets acquired and liabilities assumed operating lease right of use assets
Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued liabilities
Business combination recognized identifiable assets acquired and liabilities assumed current liabilities loan payable related party
Business combination recognized identifiable assets acquired and liabilities assumed current liabilities operating lease liability
Business combination recognized identifiable assets acquired and liabilities assumed current liabilities development agreement liability
Business combination recognized identifiable assets acquired and liabilities assumed current liabilities convertible notes payable.
Business combination recognized identifiable assets acquired and liabilities assumed current liabilities deferred tax liability.
SCN-107 [Member]
SCN-102 [Member]
Estimated future annual amortization expense.
Amended and Restated Agreement and Plan of Merger [Member]
Eat Well Investment Group Inc [Member]
Unpaid principal and accrued interest.
Legacy Note [Member]
Ten Promissory Note [Member]
Exclusive License And Commercial Agreements [Member]
Principal portion of debt repaid.
Development agreement liability current.
Development agreement liability longterm portion.
Streetville Note [Member]
Purchase Agreement [Member]
New Lease [Member]
Original debt issuance discount.
IPS Lease [Member]
Transaction costs.
Lenders transaction costs amortization.
Secured Promissory Note A-1 [Member]
Secured Promissory Note B [Member]
Option Plans [Member]
Cash and cash equivalents and restricted cash beginning of period abstract
Increase decrease in deferred offering cost.
Schedule of Intangible Assets [Table Text Block]
SCN 104 [Member]
SCN 106 [Member]
Placement agent fee.
Debt discount and issuance costs.
Single Reportable Segment [Member]
Number of reportable segments not disclosed flag.
Cash and cash equivalents and restricted cash end of period abstract.
Losartan Potassium Oral Suspension [Member]
Pharmaceutical Product Resale [Member]
Secured Promissory A-1 Note and B Note [Member]
Two Customers [Member]
Second Amended and Restated 2019 Equity Incentive Plan [Member]
Schedule of Stockholders Equity Warrant Liability Valuation Assumptions [Table Text Block]
Increase decrease in development liability.
Fair value of restricted common stock.
June 2029 [Member]
June 2030 [Member]
Assets, Current
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Interest Expense, Nonoperating
Nonoperating Income (Expense)
Income Tax Expense (Benefit)
Weighted Average Number of Shares Outstanding, Basic
Weighted Average Number of Shares Outstanding, Diluted
Shares, Outstanding
StockIssuedDuringPeriodSharesEquityLineOfCommitmentSharesIssued
Stock Issued During Period, Shares, Conversion of Units
Issuance of Stock and Warrants for Services or Claims
InterestIncome
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Inventories
IncreaseDecreaseInDeferredOfferingCost
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accrued Liabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Cash and Cash Equivalent
Restricted Cash
ConversionOfNotePayableIntoCommonStock
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Interest Income, Operating
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
Business Combination, Recognized Liability Assumed, Accounts Payable, Current
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLoanPayableRelatedParty
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOperatingLeaseLiability
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDevelopmentAgreementLiability
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesConvertibleNotesPayable
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredTaxLiability
Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill
Accounts Payable
Interest Receivable
Revenues [Default Label]
GoodwillImpairedMethodForFairValueDeterminations
Goodwill, Gross
Debt Instrument, Interest Rate During Period
Cash [Default Label]
Interest Income (Expense), Operating
Restricted Stock or Unit Expense
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price
FairValueAdjustmentOfWarrantsRoundingOff
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableWeightedAverageExercisePrice
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentExercisableIntrinsicValue
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Debt Instrument, Repaid, Principal
Interest Paid, Including Capitalized Interest, Operating and Investing Activities
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Cost of Revenue
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent